Abstract
Tuberculosis (TB) patients present dysregulated immunity, iron metabolism and anaemia of inflammation. In this study, circulatory cytokines, trace metals, and iron-related proteins (hepcidin, ferroportin, transferrin, DMT1, Nramp1, ferritin, ceruloplasmin, hemojuvelin, aconitase, transferring receptor) were monitored in case (active tuberculosis patients: ATB) and control (non-tuberculosis: NTB and healthy) study populations (n=72, male, 42.94 mean age (16-83)). Using serum elemental and cytokine levels, a partial least square discriminate analysis model (PLS-DA) was built and variables with a VIP score of >0.6 were selected as important markers. A biosignature of IL-13, IL-12(p70), IFN-γ, IL-10, IL-5, IL-18, IL-4, Selenium, and Aluminium clustered ATB away from controls. Interestingly, low iron and selenium levels, while high copper and aluminum levels were observed in ATB subjects. All the important serum cytokines were positively correlated in ATB subjects. A low abundance of transferrin, ferroportin, and hemojuvelin, while higher ferritin and ceruloplasmin levels explained an altered iron metabolism in ATB subjects which partially resolved upon completion of treatment. Further, the identified biosignature in TB patients, that explained anemia of inflammation, along with perturbed iron homeostasis could be useful targets for the development of host-directed adjunct therapeutics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge the Department of Biotechnology (DBT), Government of India for supporting activities through research grants (BT/510/NE/TBP/2013 dated 11-08-2014 and MDR-TB/2017/39) and ICGEB New Delhi for providing access to ICP-MS facility and core support. Sandeep R. Kaushik received Senior Research Fellowship from the DBTand Sukanya Sahu received support from the Council of Scientific and Industrial Research (CSIR) New Delhi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was part of a project activity approved by the institutional review board and ethics committees of Agartala Government Medical College-Agartala (protocolF.4[6-9]/AGMC/Academic/IEC Committee/2015/8965, dated 25 April 2018), Nagaland Hospital Authority-Kohima (NHAK/HLRC/RES-3/2013/64), Assam Medical College-Dibrugarh (AMC/EC/PG/3530) and International Centre for Genetic engineering and Biotechnology (ICGEB) New Delhi (ICGEB/IEC/2014/07).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred in this article will be shared to the requesting readers with appropriate justification.
